( July 2, 2025, 2:52 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals denied a biopharmaceutical company’s petition for rehearing en banc in a July 1 order, rejecting the company’s contention that an appeals court panel improperly analyzed its intent to encourage practitioners to use its antipsychotic medication in a way that would infringe on another company’s patented injectable medication used to treat schizophrenia....